CVS Health Corporation

NYSE:CVS

Medical - Healthcare Plans

Healthcare
$81.35 -0.59%

-$0.59 today

Market cap
$104.08B
Beta
0.62
P/E (TTM)
42.8
EPS (TTM)
$2.30
Dividend yield
2.70%
52W Low $58.50High $102.77

Volume 17.19M

Average 8.19M

CVS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

CVS Health CorporationNYSE: CVS

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA growth accelerates

Q2 FY2026 EBITDA of $5.86B rose 63.6% year over year, ahead of the -5.4% change in trailing-twelve-month EBITDA. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at -7.2% a year.

Context

  • EBITDA amounted to 2.5% of revenue in FY2025, down 1.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 17 analysts of $20.9B (+112.0%) for the fiscal year ending Dec 2026, a step up from the -27.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.86B+0.6% QoQ
Last fiscal yearDec 2025
$9.86B-27.9% YoY
LTMJun 2026
$13.41B-5.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+63.6%+398.4%+334.7 pp
1 year-27.9%+112.0%+139.9 pp
3-year CAGR-7.2%+32.8%+40.1 pp
5-year CAGR+21.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
9.86B USD
Year-over-year change
-27.9%
4-year CAGR
-13.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CVS compares with its peers on the latest reported figures

  • CVS's LTM Jun 2026 EBITDA of $13.41B is the 2nd highest of the 9 companies compared; the peer median is $1.94B.
  • Its year-over-year change of -5.4% is the 5th highest of 9, against a peer median of -3.5%.
  • EBITDA amounts to 3.2% of revenue for CVS, versus a peer median of 3.1%.
CVS Competitors Peer median
EBITDA for CVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UNHUnitedHealth Group IncorporatedLTM Sep 2026$27.99B -8.3%-10.2%6.2%
CVSCVS Health CorporationLTM Jun 2026$13.41B -5.4%-7.2%3.2%
CICigna CorporationLTM Sep 2026$12.53B +1.2%+0.7%4.4%
ELVElevance Health Inc.LTM Sep 2026$8.88B -11.4%-1.6%4.4%
HUMHumana Inc.LTM Sep 2026$3.24B +4.5%-15.4%2.1%
OSCROscar Health, Inc.LTM Jun 2026$633.7M +751.9%—4.1%
MOHMolina Healthcare, Inc.LTM Sep 2026$333M -78.1%-10.2%0.8%
ALHCAlignment Healthcare, Inc.LTM Mar 2026$66.42M +265.7%—1.6%
CNCCentene CorporationLTM Jun 2026-$2.73B -158.1%—1.4%
Peer median (excluding CVS) $1.94B-3.5%-10.2%3.1%

Competitors are the stored peer set for CVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue292.11B322.47B357.78B372.81B402.07B
Cost of Revenue239.99B267.97B303.35B321.41B346.71B
Gross Profit52.12B54.5B54.43B51.4B55.36B
Gross Margin17.8%16.9%15.2%13.8%13.8%
Research & Development00000
Selling, General & Admin00041.23B0
Operating Expenses38.81B46.55B40.69B42.89B44.98B
Depreciation & Amortization4.49B4.22B4.37B4.6B4.61B
EBITDA17.53B12.35B18.2B13.68B9.86B
EBITDA Margin6.0%3.8%5.1%3.7%2.5%
Operating Income13.31B7.95B13.74B8.52B10.39B
Operating Margin4.6%2.5%3.8%2.3%2.6%
Interest Income00000
Interest Expense2.5B2.29B2.66B2.96B3.12B
Other Income / Expenses(2.77B)(2.12B)(2.57B)(2.37B)(8.25B)
Income Before Tax10.54B5.84B11.17B6.15B2.14B
Pre-Tax Margin3.6%1.8%3.1%1.6%0.5%
Income Tax Expense2.55B1.51B2.81B1.56B408M
Net Income8B4.31B8.34B4.61B1.77B
Net Margin2.7%1.3%2.3%1.2%0.4%
EPS (Basic)6.003.296.493.661.40
EPS (Diluted)5.953.266.473.661.39
Weighted Avg Shares1.32B1.31B1.29B1.26B1.27B
Weighted Avg Shares (Diluted)1.33B1.32B1.29B1.26B1.27B

CVS Health Corporation

NYSE:CVS

Intrinsic Alpha fair value

Locked

Current Price

$81.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.